Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995-2000).
OBJECTIVE
To compare use of doxorubicin, surgery, and radiation versus surgery and radiation alone for treatment of cats with vaccine-associated sarcoma.


METHODS
Retrospective study.


METHODS
25 cats with vaccine-associated sarcomas.


METHODS
Time to first recurrence and survival time were compared between the 2 treatment groups. The number of surgeries (1 or > 1) were compared with respect to time to first recurrence and survival time.


RESULTS
Median time to first recurrence was 661 days for the group that received doxorubicin, surgery, and radiation. Median time to first recurrence has not yet been attained for the group treated with surgery and radiation alone. Median survival time was 674 days for the group treated with doxorubicin, surgery, and radiation and 842 days for the group treated with surgery and radiation alone. For time to first recurrence and survival time, significant differences were not detected between cats that had 1 surgery and those that had > 1 surgery.


CONCLUSIONS
Significant differences between the 2 treatment groups were not detected. The efficacy of doxorubicin in the treatment of vaccine-associated sarcomas is uncertain.
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523, USA.
V S
VS
Bregazzi
S M
SM
LaRue
E
E
McNiel
D W
DW
Macy
W S
WS
Dernell
B E
BE
Powers
S J
SJ
Withrow
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D002415:Cats; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D004317:Doxorubicin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000662:veterinary; D018714:Radiotherapy, Adjuvant / Q000662:veterinary; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D015996:Survival Rate; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary
D000970:Antineoplastic Agents; D004317:Doxorubicin